Q4 2017 Earnings Forecast for Eli Lilly and Company (LLY) Issued By SunTrust Banks
Eli Lilly and Company (NYSE:LLY) – Research analysts at SunTrust Banks increased their Q4 2017 earnings per share (EPS) estimates for shares of Eli Lilly and in a research note issued to investors on Sunday. SunTrust Banks analyst J. Boris now expects that the company will post earnings per share of $1.11 for the quarter, up from their prior forecast of $1.10. SunTrust Banks also issued estimates for Eli Lilly and’s FY2018 earnings at $4.77 EPS, FY2019 earnings at $5.23 EPS, FY2020 earnings at $6.08 EPS and FY2021 earnings at $6.93 EPS.
Several other research analysts also recently issued reports on the stock. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the stock a “sell” rating in a research note on Tuesday. Cowen reiterated a “buy” rating and issued a $95.00 target price on shares of Eli Lilly and in a research note on Wednesday, October 4th. Jefferies Group reiterated a “buy” rating and issued a $89.00 target price (down previously from $94.00) on shares of Eli Lilly and in a research note on Thursday, August 24th. BidaskClub downgraded shares of Eli Lilly and from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $105.00 target price on shares of Eli Lilly and in a research note on Friday, October 13th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $90.25.
Shares of Eli Lilly and (LLY) opened at $86.71 on Tuesday. The firm has a market cap of $95,431.91, a PE ratio of 21.19, a price-to-earnings-growth ratio of 1.90 and a beta of 0.35. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. Eli Lilly and has a fifty-two week low of $67.54 and a fifty-two week high of $89.09.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. The business had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business’s revenue was up 9.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.88 earnings per share.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Advantus Capital Management Inc increased its stake in shares of Eli Lilly and by 0.4% in the first quarter. Advantus Capital Management Inc now owns 97,698 shares of the company’s stock worth $8,217,000 after purchasing an additional 425 shares in the last quarter. Modera Wealth Management LLC purchased a new stake in shares of Eli Lilly and in the first quarter worth $238,000. Partnervest Advisory Services LLC increased its stake in shares of Eli Lilly and by 12.4% in the first quarter. Partnervest Advisory Services LLC now owns 5,820 shares of the company’s stock worth $489,000 after purchasing an additional 643 shares in the last quarter. Stephens Inc. AR increased its stake in shares of Eli Lilly and by 4.5% in the first quarter. Stephens Inc. AR now owns 44,023 shares of the company’s stock worth $3,703,000 after purchasing an additional 1,901 shares in the last quarter. Finally, Bellevue Group AG increased its stake in shares of Eli Lilly and by 275.4% in the first quarter. Bellevue Group AG now owns 131,400 shares of the company’s stock worth $11,052,000 after purchasing an additional 96,400 shares in the last quarter. Institutional investors and hedge funds own 76.42% of the company’s stock.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 195,000 shares of the stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $85.14, for a total value of $16,602,300.00. Following the transaction, the insider now directly owns 123,513,247 shares in the company, valued at $10,515,917,849.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Susan Mahony sold 36,585 shares of the stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the completion of the transaction, the senior vice president now owns 54,885 shares in the company, valued at $4,729,989.30. The disclosure for this sale can be found here. Insiders sold 628,588 shares of company stock worth $53,399,536 over the last quarter. Insiders own 0.20% of the company’s stock.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be given a $0.5625 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a yield of 2.59%. Eli Lilly and’s dividend payout ratio (DPR) is presently 98.58%.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/q4-2017-earnings-forecast-for-eli-lilly-and-company-lly-issued-by-suntrust-banks/1761159.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.